https://www.epmmagazine.com/topics/national-institute-for-health-and-care-excellence-%28nice%29/index.rss en-gb © Rapid Life Sciences Ltd, a Rapid News Group Company. All Rights Reserved. Fri, 22 Jan 2021 11:36:25 -0000 The MS Society has described the National Institute for Health and Care Excellence’s (NICE) decision not to recommend a new treatment for people with multiple sclerosis as “frustrating”. https://www.epmmagazine.com/pharma-manufacturing-news/new-drug-development-approvals-regulatory-news/ms-sociey/ https://www.epmmagazine.com/pharma-manufacturing-news/new-drug-development-approvals-regulatory-news/ms-sociey/ Fri, 22 Jan 2021 11:36:25 -0000 MS Reece Armstrong A government ordered review into a range of medical treatments primarily targeting women has uncovered serious wrongdoing by healthcare professionals. https://www.epmmagazine.com/pharma-manufacturing-news/women-ignored-in-major-health-scandal/ https://www.epmmagazine.com/pharma-manufacturing-news/women-ignored-in-major-health-scandal/ Wed, 08 Jul 2020 09:00:00 -0000 Woman doctors Up to 1.4 million people in the UK are thought to be using cannabis for medical purposes, according to new research. https://www.epmmagazine.com/pharma-manufacturing-news/over-1-million-people-in-uk-using-cannabis-for-medical-purpo/ https://www.epmmagazine.com/pharma-manufacturing-news/over-1-million-people-in-uk-using-cannabis-for-medical-purpo/ Thu, 14 Nov 2019 11:50:00 -0000 Medical cannabis The NHS has approved an ovarian cancer treatment developed by a team of scientists at Newcastle University. https://www.epmmagazine.com/pharma-manufacturing-news/ovarian-cancer-developed-by-newcastle-university-approved-by/ https://www.epmmagazine.com/pharma-manufacturing-news/ovarian-cancer-developed-by-newcastle-university-approved-by/ Tue, 29 Oct 2019 14:45:00 -0000 Newcastle Quad Chief executive of the National Institute for Health and Care Excellence (NICE) Sir Andrew Dillon has announced he will step down from the role next year. https://www.epmmagazine.com/pharma-manufacturing-news/chief-executive-of-nice-to-step-down-after-21-years/ https://www.epmmagazine.com/pharma-manufacturing-news/chief-executive-of-nice-to-step-down-after-21-years/ Fri, 23 Aug 2019 08:55:00 -0000 Retiring A lack of clinical evidence is preventing clinicians from being able to prescribe cannabis-based medicines, an NHS review has found. https://www.epmmagazine.com/pharma-manufacturing-news/lack-of-clinical-evidence/ https://www.epmmagazine.com/pharma-manufacturing-news/lack-of-clinical-evidence/ Thu, 08 Aug 2019 23:00:00 -0000 CBD The National Institute for Health and Care Excellence (NICE) has recommended shorter courses of antibiotics in an effort to cut down on overuse and the risk of antibiotic resistant infections. https://www.epmmagazine.com/pharma-manufacturing-news/nice-recommends-shorter-courses-of-antibiotics-to-fight-resi/ https://www.epmmagazine.com/pharma-manufacturing-news/nice-recommends-shorter-courses-of-antibiotics-to-fight-resi/ Fri, 19 Jul 2019 11:15:00 -0000 Antibiotics Pharmaceutical companies will be paid to develop new drugs for resistant infections in a new incentive scheme launched by the NHS. https://www.epmmagazine.com/pharma-manufacturing-news/nhs-launches-world-s-first-incentive-scheme-for-antibiotics/ https://www.epmmagazine.com/pharma-manufacturing-news/nhs-launches-world-s-first-incentive-scheme-for-antibiotics/ Thu, 11 Jul 2019 08:50:00 -0000 Antibiotics Innovative cancer drugs are taking longer to get to patients due to delays in clinical trials and regulatory red tape, new data shows. https://www.epmmagazine.com/pharma-manufacturing-news/innovative-cancer-drugs-not-reaching-patients-fast-enough-da/ https://www.epmmagazine.com/pharma-manufacturing-news/innovative-cancer-drugs-not-reaching-patients-fast-enough-da/ Tue, 04 Dec 2018 11:35:00 -0000 Cancer drugs The National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Crysvita (burosumab) to be used in the treatment of X-linked hypophosphataemia (XLH) in children and young people with growing bones. https://www.epmmagazine.com/pharma-manufacturing-news/nice-recommends-crysvita-for-treatment-of-rare-bone-disorder/ https://www.epmmagazine.com/pharma-manufacturing-news/nice-recommends-crysvita-for-treatment-of-rare-bone-disorder/ Wed, 05 Sep 2018 13:02:25 -0000 approval Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. https://www.epmmagazine.com/pharma-manufacturing-news/the-top-five-tweets-from-achema-to-nice-guidance/ https://www.epmmagazine.com/pharma-manufacturing-news/the-top-five-tweets-from-achema-to-nice-guidance/ Fri, 15 Jun 2018 13:38:07 -0000 Top five The National Institute for Health and Care Excellence (NICE) has published its positive guidance for the first selective interleukin (IL)-23 inhibitor to treat moderate to severe plaque psoriasis. https://www.epmmagazine.com/pharma-manufacturing-news/nice-publishes-positive-guidance-for-tremfya/ https://www.epmmagazine.com/pharma-manufacturing-news/nice-publishes-positive-guidance-for-tremfya/ Thu, 14 Jun 2018 11:49:13 -0000 approval A delegate of experts from the North of England will be showcasing their excellence in tackling antimicrobial resistance (AMR) to an international conference in Boston, Massachusetts, USA. https://www.epmmagazine.com/pharma-manufacturing-news/north-of-england-experts-show-excellence-in-tackling-amr/ https://www.epmmagazine.com/pharma-manufacturing-news/north-of-england-experts-show-excellence-in-tackling-amr/ Mon, 04 Jun 2018 10:00:00 -0000 Excellence.jpg Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. https://www.epmmagazine.com/pharma-manufacturing-news/the-top-five-tweets-from-blockchain-to-chmp-opinion/ https://www.epmmagazine.com/pharma-manufacturing-news/the-top-five-tweets-from-blockchain-to-chmp-opinion/ Fri, 04 May 2018 14:00:00 -0000 Top five The National Institute for Health and Care Excellence (NICE) has issued its final appraisal determination (FAD) to Janssen recommending Tremfya (guselkumab) for treatment of adults with moderate to severe plaque psoriasis. https://www.epmmagazine.com/pharma-manufacturing-news/nice-issues-fad-for-janssens-psoriasis-treatment/ https://www.epmmagazine.com/pharma-manufacturing-news/nice-issues-fad-for-janssens-psoriasis-treatment/ Wed, 02 May 2018 09:31:04 -0000 Psoriasis The Medicines and Healthcare products Regulatory Agency (MHRA) has implemented changes to the licence for valproate medicines — Epilim, Depakote and generics used to treat epilepsy and bipolar disorder — in the interest of public safety. https://www.epmmagazine.com/pharma-manufacturing-news/mhra-changes-licence-for-valproate-medicines/ https://www.epmmagazine.com/pharma-manufacturing-news/mhra-changes-licence-for-valproate-medicines/ Tue, 24 Apr 2018 12:44:30 -0000 Epilepsy Following a series of papers, published in The Lancet and featuring contributions from Professor Martin Underwood of Warwick Medical School, the NHS has published recommended changes to the treatment of low back pain. https://www.epmmagazine.com/pharma-manufacturing-news/treatment-of-low-back-pain-needs-to-change/ https://www.epmmagazine.com/pharma-manufacturing-news/treatment-of-low-back-pain-needs-to-change/ Mon, 09 Apr 2018 11:44:09 -0000 back pain London-based scientists have found a new blood test that may be able to quickly predict if a female patient is responding to the breast cancer drug, palbociclib, earlier that is possible with currently available tests. https://www.epmmagazine.com/pharma-manufacturing-news/new-blood-test-may-quickly-predict-if-palbociclib-works/ https://www.epmmagazine.com/pharma-manufacturing-news/new-blood-test-may-quickly-predict-if-palbociclib-works/ Thu, 01 Mar 2018 13:50:41 -0000 Breast cancer help A final appraisal determination (FAD) has been issued by the National Institute for Health and Care Excellence (NICE), recommending routine NHS use of avelumab for the treatment of adults in England, Wales and Northern Ireland with mMCC https://www.epmmagazine.com/pharma-manufacturing-news/avelumab-recommended-for-routine-nhs-use-by-nice/ https://www.epmmagazine.com/pharma-manufacturing-news/avelumab-recommended-for-routine-nhs-use-by-nice/ Thu, 01 Mar 2018 12:38:59 -0000 Positive opinion Breast cancer treatment, eribulin (Halaven), will still be accessible to patients with advanced metastatic breast cancer despite recent guidance by the National Institute of Health and Care Excellence (NICE), according to Eisai. https://www.epmmagazine.com/pharma-manufacturing-news/metastatic-breast-cancer-treatment-will-still-be-available/ https://www.epmmagazine.com/pharma-manufacturing-news/metastatic-breast-cancer-treatment-will-still-be-available/ Thu, 22 Feb 2018 13:39:18 -0000 Breast cancer ribbon Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. https://www.epmmagazine.com/pharma-manufacturing-news/the-top-five-tweets-from-ms-to-amr/ https://www.epmmagazine.com/pharma-manufacturing-news/the-top-five-tweets-from-ms-to-amr/ Fri, 16 Feb 2018 15:00:00 -0000 Top five The National Institute for Health and Care Excellence (NICE) has issued a final appraisal decision (FAD) recommending the reimbursement of lenvatinib (Lenvima) for the treatment of differentiated thyroid cancer. https://www.epmmagazine.com/pharma-manufacturing-news/nice-recommends-reimbursement-of-lenvatinib-for-thyroid-canc/ https://www.epmmagazine.com/pharma-manufacturing-news/nice-recommends-reimbursement-of-lenvatinib-for-thyroid-canc/ Fri, 16 Feb 2018 12:11:10 -0000 Thyroid cancer The National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending tivozanib as a first-line treatment option for advanced renal cell carcinoma (aRCC) in line with its licensed indication https://www.epmmagazine.com/pharma-manufacturing-news/nice-recommends-tivozanib-as-first-line-treatment-for-kidney/ https://www.epmmagazine.com/pharma-manufacturing-news/nice-recommends-tivozanib-as-first-line-treatment-for-kidney/ Tue, 13 Feb 2018 14:06:05 -0000 Kidney NHS England has revealed that thousands of patients have benefited from the new CDF and as a result of discounts it has secured on eight treatments, savings of around £140 million should be generated over the course of the next five years https://www.epmmagazine.com/pharma-manufacturing-news/thousands-of-patients-benefitting-from-new-cdf-says-nhs-engl/ https://www.epmmagazine.com/pharma-manufacturing-news/thousands-of-patients-benefitting-from-new-cdf-says-nhs-engl/ Mon, 29 Jan 2018 14:31:25 -0000 medicines It has been announced by Eisai that the National Institute for Health and Care Excellence (NICE) has given a positive recommendation for the use of Kisplyx (lenvatinib) in combination with everolimus for the treatment of advanced renal cell carcinoma https://www.epmmagazine.com/pharma-manufacturing-news/nice-gives-positive-recommendation-for-combination-therapy-t/ https://www.epmmagazine.com/pharma-manufacturing-news/nice-gives-positive-recommendation-for-combination-therapy-t/ Tue, 12 Dec 2017 12:13:40 -0000 Kidney Two life-extending drugs will now be available to breast cancer patients on the NHS after price negotiations lead the National Institute for Health and Care Excellence (NICE) to approve them. https://www.epmmagazine.com/pharma-manufacturing-news/two-life-extending-drugs-now-available-to-nhs-breast-cancer-/ https://www.epmmagazine.com/pharma-manufacturing-news/two-life-extending-drugs-now-available-to-nhs-breast-cancer-/ Thu, 16 Nov 2017 12:32:52 -0000 Breast cancer Patients in England will now have immediate access to the new multiple sclerosis (MS) treatment, cladribine tablets (Mavenclad), thanks to a commercial agreement between the manufacturer, Merck, and NHS England that has been announced today. https://www.epmmagazine.com/pharma-manufacturing-news/ms-patients-in-england-will-have-access-to-mavenclad-thanks-/ https://www.epmmagazine.com/pharma-manufacturing-news/ms-patients-in-england-will-have-access-to-mavenclad-thanks-/ Thu, 09 Nov 2017 12:06:49 -0000 Multiple sclerosis A new statement has been released based on a decision of the Board of the Association of the British Pharmaceutical Industry (ABPI) that it will not appeal the outcome of its judicial review application versus NICE https://www.epmmagazine.com/pharma-manufacturing-news/abpi-will-not-appeal-the-decision-by-the-judicial-review/ https://www.epmmagazine.com/pharma-manufacturing-news/abpi-will-not-appeal-the-decision-by-the-judicial-review/ Fri, 06 Oct 2017 11:36:04 -0000 Legal Opdivo, also known as nivolumab, will now be available to NHS patients suffering from lung cancer as the drug’s manufacturer, Bristol-Myers Squibb, offers the National Institute for Health and Care Excellence (NICE) a new cancer drugs fund (CDF) deal https://www.epmmagazine.com/pharma-manufacturing-news/lung-cancer-drug-now-available-on-nhs-thanks-to-new-deal/ https://www.epmmagazine.com/pharma-manufacturing-news/lung-cancer-drug-now-available-on-nhs-thanks-to-new-deal/ Wed, 20 Sep 2017 10:24:55 -0000 Lungs A new severe asthma treatment, Reslizumab, has been recommended for use on the NHS by the National Institute for Health and Care Excellence (NICE). https://www.epmmagazine.com/pharma-manufacturing-news/new-form-of-asthma-treatment-approved-for-use-on-nhs/ https://www.epmmagazine.com/pharma-manufacturing-news/new-form-of-asthma-treatment-approved-for-use-on-nhs/ Thu, 20 Jul 2017 11:18:28 -0000 Asthma treatment